Key result
Surgical repair of the tricuspid valve is the definitive therapy for tricuspid regurgitation, a complex pathology associated with decreased survival even with normal left heart function.
This review highlights the clinical impact of tricuspid regurgitation on survival and morbidity, emphasizing the need for appropriate management, especially in patients with advanced heart failure and LVADs.
Underscores need for surgical repair in tricuspid regurgitation; leaves open optimal timing and selection in advanced HF and LVAD patients.
Tricuspid regurgitation (TR) is a complex and insidious valvular pathology that represents a complex decision and management algorithm for patients. TR is present in a significant proportion of the population and is especially prevalent in patients with advanced heart failure. Patients with TR have been demonstrated to have a decreased survival even with normal left heart function. TR can be a result of pathology that directly affects the valvular structure (i.e., Ebstein anomaly) or as a result of increased forward pressures (ie, pulmonary hypertension, left heart failure). Conservative management of patients with TR is primarily symptomatic relief. Definitive therapy involves surgical repair of the tricuspid valve. Furthermore, as more patients develop advanced heart failure, the management of TR in patients with left ventricular assist devices has become necessary because of the evidence of increased in-hospital morbidity and a trend toward decreased survival.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2013) conducted a review in Tricuspid regurgitation. Surgical repair of the tricuspid valve is the definitive therapy for tricuspid regurgitation, a complex pathology associated with decreased survival even with normal left heart function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: